Trump's formal letters to major big pharma, demanding immediate action to reduce U.S. drug prices to Most-Favored-Nation (MFN) levels — i.e., the lowest prices offered in any other developed nation, represent a move by his administration to stop what he calls "global freeloading" on U.S. pharma innovation, as well as for the adminstration to lower costs for all Americans - a campaign pledge he made in 2024.
Read More.